I. Brisbane

756 total citations · 1 hit paper
4 papers, 474 citations indexed

About

I. Brisbane is a scholar working on Pulmonary and Respiratory Medicine, Organic Chemistry and Pharmaceutical Science. According to data from OpenAlex, I. Brisbane has authored 4 papers receiving a total of 474 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 1 paper in Organic Chemistry and 1 paper in Pharmaceutical Science. Recurrent topics in I. Brisbane's work include Lung Cancer Treatments and Mutations (3 papers), Brain Metastases and Treatment (2 papers) and Lung Cancer Diagnosis and Treatment (2 papers). I. Brisbane is often cited by papers focused on Lung Cancer Treatments and Mutations (3 papers), Brain Metastases and Treatment (2 papers) and Lung Cancer Diagnosis and Treatment (2 papers). I. Brisbane collaborates with scholars based in United Kingdom and Australia. I. Brisbane's co-authors include Rachael Barton, Corinne Faivre‐Finn, Ruth E. Langley, N. Bayman, Matthew Nankivell, Richard Stephens, Paula Wilson, Elaine McColl, David Ardron and Cheryl Pugh and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Radiotherapy and Oncology.

In The Last Decade

I. Brisbane

2 papers receiving 463 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial

2016 453 citations P. Mulvenna, Matthew Nankivell et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
I. Brisbane United Kingdom	2	429	330	185	57	48	4	474
Liesa Dziggel Germany	13	400 0.9×	286 0.9×	224 1.2×	56 1.0×	101 2.1×	36	469
Flávio Eduardo Prisco Brazil	5	337 0.8×	190 0.6×	211 1.1×	125 2.2×	46 1.0×	9	384
M. Paraskevaidis Greece	4	326 0.8×	243 0.7×	185 1.0×	35 0.6×	55 1.1×	12	392
R Riou France	10	335 0.8×	326 1.0×	82 0.4×	62 1.1×	31 0.6×	18	428
Antoinette Verbeek-de Kanter Netherlands	6	337 0.8×	138 0.4×	255 1.4×	94 1.6×	37 0.8×	7	362
Shari Rudoler United States	9	143 0.3×	46 0.1×	69 0.4×	98 1.7×	38 0.8×	14	348
Naoki Omachi Japan	11	358 0.8×	268 0.8×	89 0.5×	67 1.2×	50 1.0×	26	432
S. Ruiz Belgium	4	236 0.6×	147 0.4×	156 0.8×	76 1.3×	27 0.6×	4	309
Raphael Bodensohn Germany	11	192 0.4×	59 0.2×	169 0.9×	52 0.9×	35 0.7×	29	298
Homan Mohammadi United States	9	172 0.4×	133 0.4×	43 0.2×	30 0.5×	40 0.8×	25	287

Countries citing papers authored by I. Brisbane

Since Specialization

Citations

This map shows the geographic impact of I. Brisbane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Brisbane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Brisbane more than expected).

Fields of papers citing papers by I. Brisbane

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Brisbane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Brisbane. The network helps show where I. Brisbane may publish in the future.

Co-authorship network of co-authors of I. Brisbane

This figure shows the co-authorship network connecting the top 25 collaborators of I. Brisbane. A scholar is included among the top collaborators of I. Brisbane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Brisbane. I. Brisbane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

4 of 4 papers shown

1.

Mohammed, N., et al.. (2019). EP-1338 Hypofractionated Chemoradiotherapy for stage-3 Non-small cell Lung cancer-Single centre experience. Radiotherapy and Oncology. 133. S733–S733.

2.

Mulvenna, P., Matthew Nankivell, Rachael Barton, et al.. (2016). Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. The Lancet. 388(10055). 2004–2014. 453 indexed citations breakdown →

3.

Mulvenna, P., Matthew Nankivell, Rachael Barton, et al.. (2015). Whole brain radiotherapy for brain metastases from non-small lung cancer: Quality of life (QoL) and overall survival (OS) results from the UK Medical Research Council QUARTZ randomised clinical trial (ISRCTN 3826061).. Journal of Clinical Oncology. 33(15_suppl). 8005–8005. 21 indexed citations

4.

Carruthers, Ross, et al.. (2010). Toxicity of hypofractionated accelerated radiotherapy concomitant with cisplatin/vinorelbine chemotherapy for non small cell lung cancer. Lung Cancer. 67. S36–S36.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact